Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315290 | 0.87 | CREBBP (0.58) | ALDH1A1CREBBPEP300KMT2AMEN1 | |
| SCHEMBL3645168 | 0.87 | CREBBP (0.52) | CREBBPEP300KMT2AMEN1MAPT | |
| SCHEMBL10235987 | 0.86 | ALDH1A1 (0.49) | ALDH1A1CREBBPEP300KMT2AMEN1 | |
| SCHEMBL2526406 | 0.86 | CREBBP (0.48) | ALDH1A1CREBBPEP300KMT2AMEN1 | |
| SCHEMBL4310575 | 0.85 | CREBBP (0.53) | ALDH1A1CREBBPEP300KMT2AMEN1 | |
| SCHEMBL2532113 | 0.83 | HTT (0.44) | ALDH1A1CREBBPEP300KMT2AMEN1 | |
| SCHEMBL4313076 | 0.83 | CREBBP (0.49) | ALDH1A1CREBBPEP300KMT2AMEN1 | |
| SCHEMBL4490282 | 0.82 | PPM1D (0.49) | ALDH1A1CREBBPEP300MAPTHPGD | |
| SCHEMBL3809200 | 0.82 | KMT2A (0.48) | ALDH1A1CREBBPEP300KMT2AMEN1 | |
| SCHEMBL12188527 | 0.81 | ICAM1 (0.45) | ALDH1A1CREBBPEP300KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2170345-B1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20110062165-A1 | BALANCED INDIVIDUAL DINING PLATE | ALLERGAN INC | 2011-03-17 | — | — | US | disclosed |
| EP-2170345-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006370-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | CYP11B2, CYP11B1, HMGCR | ALDH1A1 503/4885CREBBP 1226/4885EP300 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.